Biowaiver monographs for immediate release solid oral dosage forms: ciprofloxacin hydrochloride

J Pharm Sci. 2011 Jan;100(1):22-33. doi: 10.1002/jps.22259.

Abstract

Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of new multisource and reformulated immediate release (IR) solid oral dosage forms containing ciprofloxacin hydrochloride as the only active pharmaceutical ingredient (API) are reviewed. Ciprofloxacin hydrochloride's solubility and permeability, its therapeutic use and index, pharmacokinetics, excipient interactions and reported BE/bioavailability (BA) problems were taken into consideration. Solubility and BA data indicate that ciprofloxacin hydrochloride is a BCS Class IV drug. Therefore, a biowaiver based approval of ciprofloxacin hydrochloride containing IR solid oral dosage forms cannot be recommended for either new multisource drug products or for major scale-up and postapproval changes (variations) to existing drug products.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Administration, Oral
  • Animals
  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / chemistry
  • Anti-Bacterial Agents / pharmacokinetics*
  • Anti-Bacterial Agents / therapeutic use
  • Biological Availability
  • Ciprofloxacin / administration & dosage*
  • Ciprofloxacin / chemistry
  • Ciprofloxacin / pharmacokinetics*
  • Ciprofloxacin / therapeutic use
  • Dosage Forms
  • Drug Approval
  • Excipients
  • Humans
  • Intestinal Absorption
  • Permeability
  • Solubility
  • Therapeutic Equivalency

Substances

  • Anti-Bacterial Agents
  • Dosage Forms
  • Excipients
  • Ciprofloxacin